AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19438584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 683
Study 19438584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study 17418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (cooled to 32 approximately 34 degrees C) in Group GCS 7 ‐ 8
Number of subjects: 148
Study 17418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia in Group GCS 5 ‐ 6
Number of subjects: 148
Study 17418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia in Group GCS 3 ‐ 4
Number of subjects: 148
Study 17418039 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control) in all groups
Number of subjects: 148
Study 14981225 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet support (IS)
Number of subjects: 255
Study 14981225 — intervention group
Group type: COMPARATOR
Intervention: Minimal in‐person support (M‐IPS)
Number of subjects: 255
Study 14981225 — intervention group
Group type: COMPARATOR
Intervention: Frequent in‐person support (F‐IPS)
Number of subjects: 255
Study 11275934 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized semiautomated PISA method for quantifying MR
Number of subjects: 75
Study 9893656 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 320 mg/day (two 160 mg tablets/day)
Number of subjects: 42
Study 9893656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8017124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried preparation of bifidumbacterin administered for 4-6 days
Number of subjects: 225
Study 8017124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried preparation of bifidumbacterin
Number of subjects: 225
Study 8017124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 225
Study 2681838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository (50 to 100 mg)
Number of subjects: 19
Study 2681838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusion
Number of subjects: 19
Study 476300 — intervention group
Group type: COMPARATOR
Intervention: Platelet transfusion alone
Number of subjects: 19
Study 30632656 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 110
Study 30632656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 27906800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 10⁸ CFU daily
Number of subjects: 55
Study 27906800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 25864240 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% nHAP toothpaste
Number of subjects: 80
Study 25864240 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% nHAP toothpaste
Number of subjects: 80
Study 25864240 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaMin toothpaste
Number of subjects: 80
Study 25864240 — intervention group
Group type: COMPARATOR
Intervention: Na-MFP toothpaste
Number of subjects: 80
Study 24063578 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment including Lugol's iodine staining
Number of subjects: 300
Study 24063578 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical treatment arm
Number of subjects: 300
Study 21133820 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 41
Study 19215190 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine/oxaliplatin)
Number of subjects: 0
Study 19215190 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX6 (5Fluorouracil/leucovorin/oxaliplatin)
Number of subjects: 0
Study 17234518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 190
Study 17234518 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 190
Study 12902895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy
Number of subjects: 2261
Study 12902895 — intervention group
Group type: COMPARATOR
Intervention: BCG immunotherapy
Number of subjects: 2261
Study 10518847 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) at total daily doses of 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg
Number of subjects: 1017
Study 10518847 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 1017
Study 10518847 — intervention group
Group type: COMPARATOR
Intervention: Conventional asthma therapy (CAT)
Number of subjects: 1017
Study 7567406 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Harvard Step Test)
Number of subjects: 65
Study 7567406 — intervention group
Group type: COMPARATOR
Intervention: Inactive period (Control)
Number of subjects: 65
Study 1837606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dynamic back extensor exercises (30 sessions over 3 months)
Number of subjects: 105
Study 1837606 — intervention group
Group type: COMPARATOR
Intervention: Alternative group (1/5 of the treatment group's exercise program per session)
Number of subjects: 105
Study 1837606 — intervention group
Group type: COMPARATOR
Intervention: Alternative group (thermotherapy, massage, and mild exercise)
Number of subjects: 105
Study 1837606 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (completed training at least once a week for 1 year)
Number of subjects: 105
Study 7019266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% stannous fluoride (SnF2), rinsed twice daily for 5 days
Number of subjects: 4
Study 7019266 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine digluconate, rinsed twice daily for 5 days after SnF2
Number of subjects: 4
Study 28844651 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising vowel formant frequencies (FFs) for vowels /ɑ/ and /æ/
Number of subjects: 0
Study 28844651 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising FFs for all four vowels
Number of subjects: 0
Study 28844651 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual analysis of vowels and formants
Number of subjects: 0
Study 27508917 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized and telephone nursing counseling for 7 months (Intervention group)
Number of subjects: 109
Study 27508917 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional consultation plus personalized and telephone nursing counseling for 7 months (Intervention group)
Number of subjects: 109
Study 27508917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 109
Study 24376067 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured practice group (SPG)
Number of subjects: 22
Study 24376067 — intervention group
Group type: COMPARATOR
Intervention: Unstructured practice group (UPG)
Number of subjects: 22
Study 22885649 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 13
Study 22885649 — intervention group
Group type: COMPARATOR
Intervention: PS
Number of subjects: 13
Study 20117965 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPCT
Number of subjects: 329
Study 20117965 — intervention group
Group type: COMPARATOR
Intervention: BMT
Number of subjects: 329
Study 18377231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear points' pressing at 5 ear meridian points
Number of subjects: 38
Study 18377231 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 38
Study 15948743 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (81 mg Connaught strain)
Number of subjects: 209
Study 15948743 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (50 mg)
Number of subjects: 209
Study 11837383 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg single oral dose in fasting state
Number of subjects: 100
Study 11837383 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg single oral dose in postprandial state
Number of subjects: 100
Study 11837383 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg single oral dose
Number of subjects: 100
Study 11837383 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg once daily for 5 days
Number of subjects: 100
Study 10445897 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group with access to case management and community care benefits (up to $699 per month)
Number of subjects: 5307
Study 10445897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to case management or community care benefits)
Number of subjects: 5307
Study 8665543 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 5 mg selegeline
Number of subjects: 30
Study 8665543 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 10 mg selegeline
Number of subjects: 30
Study 8665543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1706014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 300 mg
Number of subjects: 96
Study 1706014 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 96
Study 1706014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (enalapril 20 mg + sustained-release diltiazem 300 mg)
Number of subjects: 96
Study 6944548 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ovarian ablation
Number of subjects: 0
Study 6944548 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30610862 — intervention group
Group type: EXPERIMENTAL
Intervention: FMTv (Fecal Microbiota Transplantation after 4-10 days of vancomycin 125 mg 4 times daily)
Number of subjects: 64
Study 30610862 — intervention group
Group type: COMPARATOR
Intervention: fidaxomicin (200 mg twice daily for 10 days)
Number of subjects: 64
Study 30610862 — intervention group
Group type: COMPARATOR
Intervention: vancomycin (125 mg 4 times daily for 10 days)
Number of subjects: 64
Study 28751244 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 28751244 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 25051005 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 times a week, in the afternoon, 6‐7 repetitions, at 85% of 1 repetition maximum for 3 weeks)
Number of subjects: 20
Study 25051005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise during the 3 weeks)
Number of subjects: 20
Study 25051005 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 20
Study 23512093 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (hi-IMT)
Number of subjects: 22
Study 23512093 — intervention group
Group type: COMPARATOR
Intervention: Sham inspiratory muscle training (sham-IMT)
Number of subjects: 22
Study 21874947 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-midvastus (MV) approach
Number of subjects: 61
Study 21874947 — intervention group
Group type: COMPARATOR
Intervention: mini-parapatellar approach
Number of subjects: 61
Study 21874947 — intervention group
Group type: COMPARATOR
Intervention: standard parapatellar approach
Number of subjects: 61
Study 21874947 — intervention group
Group type: COMPARATOR
Intervention: mini-subvastus approach
Number of subjects: 61
Study 19819004 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified killed-whole-cell cholera vaccine
Number of subjects: 107774
Study 19819004 — intervention group
Group type: COMPARATOR
Intervention: Heat-killed Escherichia coli K12 placebo
Number of subjects: 107774
Study 17101886 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 10‐Hz rTMS
Number of subjects: 22
Study 17101886 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study 14508197 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 10
Study 10811079 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin monotherapy
Number of subjects: 32
Study 10811079 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine monotherapy
Number of subjects: 32
Study 8968432 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of hydrochlorothiazide, atenolol, captopril, diltiazem‐SR, clonidine, and prazosin
Number of subjects: 102
Study 8968432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin after diltiazem
Number of subjects: 102
Study 8968432 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem after prazosin
Number of subjects: 102
Study 8968432 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril-diltiazem
Number of subjects: 102
Study 8968432 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-captopril
Number of subjects: 102
Study 1319735 — intervention group
Group type: EXPERIMENTAL
Intervention: L (80 mg/day lovastatin)
Number of subjects: 62
Study 1319735 — intervention group
Group type: EXPERIMENTAL
Intervention: L + GG (80 mg/day lovastatin + 20 g/day guar gum)
Number of subjects: 62
Study 1319735 — intervention group
Group type: EXPERIMENTAL
Intervention: L + C (80 mg/day lovastatin + 16 g/day cholestyramine)
Number of subjects: 62
Study 6381570 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert group
Number of subjects: 396
Study 6381570 — intervention group
Group type: COMPARATOR
Intervention: Nonalert group
Number of subjects: 396
Study 30951267 — intervention group
Group type: EXPERIMENTAL
Intervention: Treating early, intensively and to target (specific treatment details not provided)
Number of subjects: 333
Study 30951267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid and persistent disease control
Number of subjects: 333
Study 30951267 — intervention group
Group type: COMPARATOR
Intervention: Treatment type (not specified)
Number of subjects: 333
Study 28328346 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, oral bovine rotavirus pentavalent vaccine (BRV-PV)
Number of subjects: 3508
Study 28328346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3508
Study 26336050 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS intervention group
Number of subjects: 31
Study 26336050 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 31
Study 23515453 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 43553 (25-900 mg)
Number of subjects: 159
Study 23515453 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 43902 (30-300 mg)
Number of subjects: 159
Study 23515453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 159
Study 20980485 — intervention group
Group type: COMPARATOR
Intervention: Serum concentrations of 25(OH)D ≥ 30 ng/mL
Number of subjects: 3085
Study 20980485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin D intake (for premenopausal women)
Number of subjects: 3085
Study 19803572 — intervention group
Group type: EXPERIMENTAL
Intervention: Battlemind debriefing
Number of subjects: 2297
Study 19803572 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group Battlemind training
Number of subjects: 2297
Study 19803572 — intervention group
Group type: EXPERIMENTAL
Intervention: Large group Battlemind training
Number of subjects: 2297
Study 19803572 — intervention group
Group type: COMPARATOR
Intervention: Stress education
Number of subjects: 2297
Study 17081209 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat ablation after CPVA
Number of subjects: 47
Study 14991627 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 surgery
Number of subjects: 221
Study 14991627 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 surgery
Number of subjects: 221
Study 11703423 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 30
Study 11703423 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study 9826140 — intervention group
Group type: EXPERIMENTAL
Intervention: y-axis inverted imaging conditions
Number of subjects: 22
Study 9826140 — intervention group
Group type: COMPARATOR
Intervention: normal imaging conditions
Number of subjects: 22
Study 8085125 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% glucose solution
Number of subjects: 10
Study 8085125 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose solution
Number of subjects: 10
Study 8085125 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glucose solution
Number of subjects: 10
Study 8085125 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucose solution)
Number of subjects: 10
Study 2713604 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk tube
Number of subjects: 70
Study 2713604 — intervention group
Group type: COMPARATOR
Intervention: Standard tube
Number of subjects: 70
Study 1067480 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with 6 mercaptopurine (6 MP) and methotrexate (MTX)
Number of subjects: 129
Study 1067480 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 6 mercaptopurine (6 MP), methotrexate (MTX) and cyclophosphamide (Cyclo)
Number of subjects: 129
Study 1067480 — intervention group
Group type: COMPARATOR
Intervention: CNS prophylaxis with cranial radiation (2500 rad) and intrathecal administration of methotrexate (MTX) and prednisolone
Number of subjects: 129
Study 1067480 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment including induction therapy with vincristine (VCR) and prednisone (Pred)
Number of subjects: 129
Study 1067480 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment including maintenance therapy
Number of subjects: 129
Study 31274491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 65
Study 31274491 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 65
Study 28379861 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-Release Injectable Naltrexone (XR-NTX) 380 mg, 6 monthly doses
Number of subjects: 100
Study 28379861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28379861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both XR-NTX and Placebo
Number of subjects: 100
Study 24460005 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump 10 group (10 jumps, twice daily for 16 weeks)
Number of subjects: 60
Study 24460005 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump 20 group (20 jumps, twice daily for 16 weeks)
Number of subjects: 60
Study 24460005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 23411791 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training combined with conventional physical therapy training
Number of subjects: 30
Study 23411791 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy training
Number of subjects: 30
Study 21562064 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Number of subjects: 565
Study 21562064 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 565
Study 21562064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 19223559 — intervention group
Group type: COMPARATOR
Intervention: HPV 16/18 infection
Number of subjects: 553
Study 19223559 — intervention group
Group type: COMPARATOR
Intervention: Other HR-HPVs
Number of subjects: 553
Study 19223559 — intervention group
Group type: COMPARATOR
Intervention: Persistent HPV 16/18 infection
Number of subjects: 553
Study 16566621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 40
Study 16566621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15321054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt beta brachytherapy (immediately after intervention, n=21)
Number of subjects: 39
Study 15321054 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed beta brachytherapy (24 h later, n=18)
Number of subjects: 39
Study 10357422 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution pulsed and color Doppler ultrasound
Number of subjects: 71
Study 7594160 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests including KOLT and retention on WLM and WVR
Number of subjects: 60
Study 7594160 — intervention group
Group type: EXPERIMENTAL
Intervention: KOLT and retention on WLM and WVR
Number of subjects: 60
Study 7594160 — intervention group
Group type: EXPERIMENTAL
Intervention: Wechsler's Logical Memory and Visual Reproduction tasks, Kendrick's Object Learning Test
Number of subjects: 60
Study 7594160 — intervention group
Group type: COMPARATOR
Intervention: Standard mental status scales
Number of subjects: 60
Study 1954080 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms, 3.5 x 10(‐7) M)
Number of subjects: 12
Study 1954080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6165954 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrin
Number of subjects: 0
Study 6165954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6142208 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant therapy (30 mg dipalmitoylphosphatidylcholine and 3 mg high-density lipoprotein in a 5 ml suspension)
Number of subjects: 100
Study 6142208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 100
Study 6142208 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant therapy
Number of subjects: 100
Study 29974563 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based group counselling with HBCSS
Number of subjects: 532
Study 29974563 — intervention group
Group type: EXPERIMENTAL
Intervention: HBCSS alone
Number of subjects: 532
Study 29974563 — intervention group
Group type: COMPARATOR
Intervention: Self-help guidance-based group counselling (SHG)
Number of subjects: 532
Study 29974563 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 532
Study 27417074 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainwave music (BWM)
Number of subjects: 36
Study 27417074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 36
Study 27417074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 24661511 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (amoxicillin 40 mg/(kg·d), Tid; clarithromycin 15 mg/(kg·d), Bid; omeprazole 0.7-0.8 mg/(kg·d), Qd)
Number of subjects: 240